Hemophilia Federation of America is a national nonprofit organization that assists, educates and advocates for the bleeding disorders community.
Note: The following is an edited version of a press release from Bayer. The original press release can be found here.聽 The U.S. Food and Drug Administration (FDA) has approved Bayer鈥檚 KOVALTRY庐 Antihemophilic Factor (Recombinant), an unmodified, full-length factor VIII compound for the treatment of hemophilia A in children and adults. The approval is based […]
聽Note: The following is an edited press release from Octapharma USA. The original release can be read in its entirety聽here. Octapharma USA announced on Monday, January 4, 2016 that NUWIQ庐, Antihemophilic Factor (Recombinant), is now commercially available. NUWIQ庐 is indicated for the treatment and control of bleeding, perioperative (surgical) management, and routine prophylaxis to reduce […]
This past weekend, the聽American Society of Hematology (ASH), a worldwide organization of 15,000+ medical and scientific experts on blood diseases,聽held their 57th Annual Meeting to discuss new treatments and research methods. During this meeting, a group of doctors from around the globe presented the findings of the Survey of Inhibitors in Plasma-Product Exposed Toddlers (SIPPET). […]
Note: The following is an edited version of a press release originally published by聽Baxalta. The original release can be read here. Baxalta Incorporated announced on Monday, November 16, 2015, that the U.S. Food and Drug Administration (FDA) has approved ADYNOVATE [Antihemophilic Factor (Recombinant), PEGylated], an extended circulating half-life recombinant Factor VIII (rFVIII) treatment for hemophilia […]
Sign up for E-mails, Dateline Magazine, and other ways to stay connected.